Hematological Toxicity in Mice after High Activity Injections of ¹⁷⁷Lu-PSMA-617.

ABSTRACT: Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., ¹⁷⁷Lu-PSMA-617, has been effective in reducing tumor burden and prolonging survival in mCRPC. However, it is not a curative method with kidney and bone marrow toxicity limiting the activity given to patients. Previous preclinical models have reported transient hematotoxicity for up to 120 MBq. This activity may still be too low to investigate the effect on renal function since it corresponds to an absorbed dose below 10 Gy, whereas the kidneys in a clinical setting usually receive an absorbed dose more than double. Here we inv

SUBMITTER: Kristiansson A 

PROVIDER: S-EPMC9032768 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature